Home  |  Archive  |  Online Submission  |  News & Events  |  Subscribe  |  APFA  |  Society  |  Links  |  Contact Us  |  中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

Links

Meetings
Journals
Societies & Institutes
Hospitals
Databases & Libraries
Companies
Websites
Other links

 
Abstract

Volume 16, Issue 4 (July 2014) 16, 505–510; 10.4103/1008-682X.125410

Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research

Rahul A Parikh1, Laura E Pascal2, Benjamin J Davies2, Zhou Wang3

1 Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Hillman Cancer Centre, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
2 Department of Urology, University of Pittsburgh School of Medicine, Hillman Cancer Centre, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
3 Division of Hematology/Oncology; Department of Urology; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Hillman Cancer Centre, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

Correspondence: Dr. Z Wang (wangz2@upmc.edu)

Received: 30 October 2013; Revised: 17 December 2013; Accepted: 17 December 2013

Abstract

Intermittent androgen deprivation therapy (IADT) is an alternative to continuous androgen deprivation therapy (ADT) in prostate cancer patients with nonmetastatic disease. ADT is associated with numerous side effects such as hot flashes, sexual dysfunction, anemia, fatigue, loss of muscle mass, osteoporosis, metabolic syndrome and premature cardiovascular disease. IADT was developed with the intention of improving the quality of life and to delay progression of prostate cancer to castration resistance. The benefits of slightly improved quality of life by IADT compared to ADT were demonstrated in multiple clinical trials. IADT was noted to be noninferior to ADT in patients with biochemical recurrence of prostate cancer but in studies performed in patients with metastatic prostate cancer, the results were inconclusive. Our recent studies suggested that the administration of 5 alpha-reductase inhibitors during the off-cycle of IADT can significantly prolong the survival of mice bearing androgen-sensitive prostate tumors when off-cycle duration was short. This review discusses the survival benefit of 5 alpha-reductase inhibition in IADT in animal models and the potential translation of this finding into clinic.

Keywords: 5 alpha-reductase inhibitor; androgen-responsive genes; intermittent androgen deprivation therapy (IADT); prostate cancer; testosterone

Full Text | PDF | 中文摘要 |

 
Browse:  1268
 
Copyright 1999-2017  Shanghai Materia Medica, Shanghai Jiao Tong University.  All rights reserved